StudyFinder
Search Results
1 Study Matches
Site for An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadaticinib in Pediatric Subjects with Severe Atopic Dermatitis
Phase 1, multiple-dose, open-label study consisting of two parts, male and female subjects aged 2 to 12 years with severe atopic dermatitis (eczema).
Samantha Gettle - at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
NCT03646604
SITE00000468
Inclusion Criteria:
must weight 22 pounds or moreHave a diagnosis of Atopic Dermatitis for at least 6 months
Exclusion Criteria:
Certain treatments are not allowed; coordinator will discuss specific treatments No active Hep A, Hep C or Hep B
Current participation in another clinical trial
Skin Conditions